Skip to main content

Rhodes Jason P's Form 4 filing

Dyne Therapeutics, Inc.DYN · filed Apr 30, 2026

Accession no.
0001577014-26-000006
Filed
Apr 30, 2026
Trade date
Apr 28, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 8 non-derivative transactions. Open-market sales total $4.18M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Rhodes Jason PCIK 0001577014Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 28, 2026Common StockSSaleDisposed−59,870$18.38F2−$1,100,410.61,577,432Indirect
Apr 28, 2026Common StockSSaleDisposed−119,115$18.38F2−$2,189,333.74,939,489Indirect
Apr 28, 2026Common StockSSaleDisposed−1,170$18.38F2−$21,504.68,512Indirect
Apr 28, 2026Common StockSSaleDisposed−47,082$18.38F2−$865,367.161,158,944Indirect
Apr 28, 2026Common StockSSaleDisposed−26$19.00−$4941,577,406Indirect
Apr 28, 2026Common StockSSaleDisposed−52$19.00−$9884,939,437Indirect
Apr 28, 2026Common StockSSaleDisposed−1$19.00−$198,511Indirect
Apr 28, 2026Common StockSSaleDisposed−21$19.00−$3991,158,923Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Referenced by the price of 4 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)